Iktos, a company specializing in AI and robotics for new drug design, agreed to acquire Synsight, a biotech company applying AI and high-content cell imaging to the discovery of novel drug candidates. Financial terms were not disclosed. “I’m very happy to become part of the Iktos team and at the perspective of adding our platform to build a one-of-its-kind drug discovery engine. Iktos superior generative AI and retrosynthesis AI technology combined with our expertise in high content cellular screening and detection of molecular interactions within the cell will provide us with a competitive advantage in targeting PPIs and RPIs. I, as well as the whole Synsight team, look forward to a successful collaboration with our new colleagues,” Cyril Bauvais, Synsight Co-Founder and President.